A modified preparation (LMK03) of the oriental medicine Jangwonhwan reduces Aβ1-42 level in the brain of Tg-APPswe/PS1dE9 mouse model of Alzheimer disease

Journal of Ethnopharmacology

Volumn 130, Issue 3, 2010, Pages 578-585

  Seo, Ji Seon ^a   Jung, Eun Young ^b   Kim, Ji Hye ^a   Lyu, Yeoung Su ^b   Han, Pyung Lim ^a   Kang, Hyung Won ^b  

^a Ewha Womans University   (South Korea)

^b Wonkwang University   (South Korea)

Author keywords

A ; Alzheimer disease; Angelica gigas Nakai; LMK03 Jangwonhwan; Oriental medicine; Plaque; White Poria cocos (Schw.) Wolf

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ANGELICA GIGAS EXTRACT; CALBINDIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; HYDROGEN PEROXIDE; LMK03 JANGWONHWAN; NEUROPROTECTIVE AGENT; PLANT EXTRACT; PORIA COCOS EXTRACT; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIPPOCAMPUS; IMMUNOHISTOLOGY; MALE; MOUSE; NEUROBLASTOMA CELL; NEUROPROTECTION; NONHUMAN; ORIENTAL MEDICINE; OXIDATIVE STRESS; PROTEIN EXPRESSION; SENILE PLAQUE; ANGELICA; ANIMAL; BRAIN; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; NEUROBLASTOMA; PATHOLOGY; PATHOPHYSIOLOGY; PORIA; TRANSGENIC MOUSE; TUMOR CELL LINE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANGELICA; ANIMALS; BRAIN; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; HIPPOCAMPUS; HUMANS; MALE; MEDICINE, EAST ASIAN TRADITIONAL; MICE; MICE, TRANSGENIC; NEUROBLASTOMA; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; PLANT EXTRACTS; PORIA; AMYLOID BETA-PEPTIDES;

ANGELICA GIGAS; MUS; MUS MUSCULUS; PORIA COCOS;

EID: 77954954791     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jep.2010.05.055     Document Type: Article

References (48)

1. Anekonda T.S., Reddy P.H. Can herbs provide a new generation of drugs for treating Alzheimer's disease?. Brain Research Reviews 2005, 50:361-376.
2. Areosa S.A., Sherriff F., McShane R. Memantine for dementia. Cochrane Database of Systematic Reviews 2006, 20.
3. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nature Reviews. Neuroscience 2009, 10:333-344.
4. Cao X., Wei Z., Gabriel G.G., Li X., Mousseau D.D. Calcium-sensitive regulation of monoamine oxidase-A contributes to the production of peroxyradicals in hippocampal cultures: implications for Alzheimer disease-related pathology. BMC Neuroscience 2007, 16. 73-?
5. Cacabelos R. Pharmacogenomics and therapeutic prospects in dementia. European Archives of Psychiatry and Clinical Neuroscience 2008, 1:28-47.
6. 2+-induced cell death in vitro and in vivo. Journal of Neuroscience Research 2003, 74:736-743.
7. Chohan M.O., Iqbal K. From tau to toxicity: emerging roles of NMDA receptor in Alzheimer's disease. Journal of Alzheimer's Disease 2006, 10:81-87.
8. Ferri C.P., Prince M., Brayne C., et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005, 366:2112-2117.
9. Finch C.E., Morgan T.E. Systemic inflammation, infection, ApoE alleles, and Alzheimer disease: as position paper. Current Alzheimer Research 2007, 4:185-189.
10. Fox N.C., Black R.S., Gilman S., et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005, 64:1563-1572.
11. Francis P.T., Ramirez M.J., Lai M.K. Neurochemical basis for symptomatic treatment of Alzheimer's Disease. Neuropharmacology 2010.
12. Frank B., Gupta S. A review of antioxidants and Alzheimer's disease. Annals of Clinical Psychiatry 2005, 17:269-286.
13. Gilman S., Koller M., Black R.S., et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562.
14. Ghosh A.K., Hong L., Tang J. Beta-secretase as a therapeutic target for inhibitor drugs. Current Medicinal Chemistry 2002, 9:1135-1144.
15. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
16. Hills I.D., Vacca J.P. Progress toward a practical BACE-1 inhibitor. Current Opinion in Drug Discovery and Development 2007, 10:383-391.
17. Huh, J., 1610. Donguibogam. Reprinted by Namsandang Press in 1994, Seoul.
18. Iacopino A.M., Christakos S. Specific reduction of calcium binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. Proceedings of the National Academy of Sciences of the United States of America 1990, 87:4078-4082.
19. Im J.Y., Kim D., Paik S.G., Han P.L. Cyclooxygenase-2-dependent neuronal death proceeds via superoxide anion generation. Free Radical Biology and Medicine 2006, 41:960-972.
20. Imbimbo B.P. Therapeutic potential of gamma-secretase inhibitors and modulators. Current Topics in Medicinal Chemistry 2008, 8:54-61.
21. Jankowsky J.L., Slunt H.H., Ratovitski T., Jenkins N.A., Copeland N.G., Borchelt D.R. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomolecular Engineering 2001, 17:157-165.
22. Kim T.W., Tanzi R.E. Presenilins and Alzheimer's disease. Current Opinion in Neurobiology 1997, 7:683-688.
23. Korea Food and Drug Administration, 2008. The Korean Pharmacopoeia IX. 9th. Seoul. Sinnilbooks Press Inc.
24. Kowalska A., Pruchnik-Wolinska D., Florczak J., et al. Genetic study of familial cases of Alzheimer's disease. Acta Biochimica Polonica 2004, 51:245-252.
25. Lee H.G., Zhu X., Castellani R.J., Nunomura A., Perry G., Smith M.A. Amyloid-beta in Alzheimer disease: the null versus the alternate hypothesis. Journal of Pharmacology and Experimental Therapeutics 2007, 321:823-829.
26. Lee K.W., Im J.Y., Song J.S. Progressive neuronal loss and behavioral impairments of transgenic C57BL/6 inbred mice expressing the carboxy terminus of amyloid precursor protein. Neurobiology of Disease 2006, 22:10-24.
27. Lee K.W., Lee S.H., Kim H. Progressive cognitive impairment and anxiety induction in the absence of plaque deposition in C57BL/6 inbred mice expressing transgenic amyloid precursor protein. Journal of Neuroscience Research 2004, 76:572-580.
28. Lee K.W., Kim J.B., Seo J.S., et al. Behavioral stress accelerates plaque pathogenesis in the brain of Tg2576 mice via generation of metabolic oxidative stress. Journal of Neurochemistry 2009, 108:165-175.
29. Leuba G., Kraftsik R., Saini K. Quantitative distribution of parvalbumin, calretinin, and calbindin D-28k immunoreactive neurons in the visual cortex of normal and Alzheimer cases. Experimental Neurology 1998, 152:278-291.
30. Luo Y., Bolon B., Kahn S., et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nature Neuroscience 2001, 4:231-232.
31. Ma Q.L., Harris-White M.E., Ubeda O.J., et al. Evidence of Abeta- and transgene-dependent defects in ERK-CREB signaling in Alzheimer's models. Journal of Neurochemistry 2007, 103:1594-1607.
32. Markesbery W.R., Carney J.M. Oxidative alterations in Alzheimer's disease. Brain Pathology 1999, 9:133-146.
33. Middleton L.E., Yaffe K. Promising strategies for the prevention of dementia. Archives of Neurology 2009, 66:1210-1215.
34. Noorbakhsh F., Overall C.M., Power C. Deciphering complex mechanisms in neurodegenerative diseases: the advent of systems biology. Trends in Neuroscience 2009, 22:88-100.
35. Onyango I.G., Khan S.M. Oxidative stress, mitochondrial dysfunction, and stress signaling in Alzheimer's disease. Current Alzheimer Research 2006, 3:339-349.
36. Palop J.J., Jones B., Kekonius L., Chin J., Yu G.Q. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:9572-9577.
37. Panza F., Solfrizzi V., Frisardi V., et al. Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators. Drugs Aging 2009, 26:537-555.
38. Schenk D., Barbour R., Dunn W., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
39. Selkoe D.J. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends in Cell Biology 1998, 8:447-453.
40. Seo J.S., Kim T.K., Leem Y.H. SK-PC-B70M confers anti-oxidant activity and reduces Aβ levels in the brain of Tg2576 mice. Brain Research 2009, 1261:100-108.
41. Seshadri S., Beiser A., Selhub J., et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. New England Journal 2002, 14:476-483.
42. Seo J.S., Yun J.H., Baek I.S., Leem Y.H., Kang H.W., Cho H.K., Lyu Y.S., Son H.J., Han P.L. Oriental medicine Jangwonhwan reduces Abeta(1-42) level and beta-amyloid deposition in the brain of Tg-APPswe/PS1dE9 mouse model of Alzheimer disease. Journal of Ethnopharmacology 2010, 128:206-212.
43. Solomon B. Antibody-mediated immunotherapy for Alzheimer's disease. Current Opinion in Investigational Drugs 2007, 8:519-524.
44. Wang X., Su B., Zheng L., Perry G., Smith M.A., Zhu X. The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease. Journal of Neurochemistry 2009, 109:153-159.
45. Yamamoto-Sasaki M., Ozawa H., Saito T., Rosler M., Riederer P. Impaired phosphorylation of cyclic AMP response element binding protein in the hippocampus of dementia of the Alzheimer type. Brain Research 1999, 824:300-303.
46. Yu Y.M., Han P.L., Lee J.K. JNK pathway is required for retinoic acid-induced neurite outgrowth of human neuroblastoma, SH-SY5Y. Neuroreport 2003, 14:941-945.
47. Zhong N., Weisgraber K.H. Understanding the basis for the association of apoE4 with Alzheimer's disease: opening the door for therapeutic approaches. Current Alzheimer Research 2009, 6:415-418.
48. Zhu X., Su B., Wang X., Smith M.A., Perry G. Causes of oxidative stress in Alzheimer disease. Cellular and Molecular Life Sciences 2007, 64:2202-2210.